Eye-Movement Intervention for Cognitive Impairment Across Schizophrenia Spectrum

Starting soon · Not applicable

Conditions studied: Schizophrenia, Cognitive Impairment, Clinical High Risk for Psychosis

In brief

The goal of this clinical trial is to determine whether a gamified eye-movement intervention can improve cognitive function in individuals across the schizophrenia spectrum, including clinical high-risk individuals, first-episode schizophrenia patients, and chronic schizophrenia patients. The main questions it aims to answer are: * Does eye-movement training improve cognitive performance measured by the MATRICS Consensus Cognitive Battery (MCCB)? * Does eye-movement training improve oculomotor functions and clinical symptoms across different illness stages? Researchers will compare an eye-movement intervention group with an active control group receiving matched finger-controlled game training to determine whether the eye-movement intervention produces greater improvements in cognitive function and eye-movement performance. Participants will: * Receive either gamified eye-movement training or matched finger-controlled game training for 4 weeks. * Complete cognitive assessments using the MCCB before and after the intervention. * Complete standardized eye-tracking tasks, including fixation stability, smooth pursuit, antisaccade, and free-viewing tasks, to evaluate changes in oculomotor control and visual exploration patterns. * Complete clinical symptom assessments using SOPS or PANSS according to illness stage.

Key facts

Study ID

NCT07702526

Run by

Shanghai Mental Health Center

People needed

160

Starts

2026-07-01

Expected to finish

2028-07-30

Last updated by the study team

2026-07-14

Who can join

Age: 15 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age between 15 and 45 years.
• More than 9 years of education.
• Normal or corrected-to-normal vision without color blindness, color weakness, strabismus, or nystagmus.
• Right-handedness.
• Impaired cognitive performance defined as a T-score <40 in at least one MCCB cognitive domain at baseline.
• Capacity to complete cognitive and eye-tracking assessments.
• Clinical high-risk group: Meet psychosis-risk syndrome criteria based on SIPS/SOPS, including attenuated positive symptoms or brief intermittent psychotic symptoms.
• First-episode schizophrenia group: Meet DSM-5 criteria for schizophrenia, with first episode occurring within approximately 2 years of illness onset and minimal prior antipsychotic exposure.
• Chronic schizophrenia group: Meet DSM-5 criteria for schizophrenia, with illness duration ≥5 years and stable treatment status for the previous 6 months.
• Healthy control group: No current or past psychiatric disorders based on MINI 7.0 and no significant depressive symptoms based on the Hamilton Depression Rating Scale. Healthy controls will also meet the same general criteria regarding age, education, handedness, and vision.

You may not qualify if…

• IQ <70.
• Severe or unstable medical or neurological illness (e.g., stroke, epilepsy, dementia, cardiac disease, or uncontrolled hypertension).
• Substance abuse or dependence.
• Clinically significant laboratory abnormalities.
• Visual or auditory impairments affecting task performance.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.